U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H22O3
Molecular Weight 310.3869
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AVOBENZONE

SMILES

COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C

InChI

InChIKey=XNEFYCZVKIDDMS-UHFFFAOYSA-N
InChI=1S/C20H22O3/c1-20(2,3)16-9-5-14(6-10-16)18(21)13-19(22)15-7-11-17(23-4)12-8-15/h5-12H,13H2,1-4H3

HIDE SMILES / InChI
Molecular Formula C20H22O3
Molecular Weight 310.3869
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.wikidoc.org/index.php/Avobenzone | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3fd7fb-4a28-4db8-9a4d-d7fdd2e45daf

Avobenzone is an oil soluble ingredient used in sunscreen products to absorb the full spectrum of UVA rays. It helps prevent sunburn. Avobenzone works by absorbing the rays and converting them to energy that is less damaging to the skin.

Originator

Approval Year

1988
111
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8429
SHADE UVAGUARD

Approved Use

helps prevent sunburn; higher SPF gives more sunburn protection; helps provide protection from UVA rays (short and long wavelengths).

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.5 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31058986
0.81 g 4 times / day multiple, topical
dose: 0.81 g
route of administration: Topical
experiment type: MULTIPLE
co-administered:
AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.1 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31058986
0.81 g 4 times / day steady-state, topical
dose: 0.81 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
45.2 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31058986
0.81 g 4 times / day steady-state, topical
dose: 0.81 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.7 g 1.3 times / day multiple, topical (median)
Recommended
Dose: 3.7 g, 1.3 times / day
Route: topical
Route: multiple
Dose: 3.7 g, 1.3 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 3.69 years (range: 0.64-48.15 years)
n = 79
Health Status: healthy
Age Group: 3.69 years (range: 0.64-48.15 years)
Sex: M+F
Population Size: 79
Sources:
https://www.fda.gov/media/71361/download
Other AEs: Dermatitis, Eczema...
Other AEs:
Dermatitis (2.5%)
Eczema (1.3%)
Sources:
https://www.fda.gov/media/71361/download
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Other AEs: Acne, Dermatitis...
Other AEs:
Acne (4.8%)
Dermatitis (2.8%)
Dry skin (1.2%)
Eczema (1.2%)
Erythema (1.2%)
Pruritus (2%)
Rosacea (0.4%)
Seborrhea (0.8%)
Skin discomfort (1.2%)
Sunburn (0.8%)
Conjunctivitis (0.8%)
Taste perversion (0.4%)
Sources:
https://www.fda.gov/media/71361/download
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
https://www.fda.gov/media/71361/download
Other AEs: Dermatitis, Eczema...
Other AEs:
Dermatitis (2.8%)
Eczema (0.4%)
Erythema (0.8%)
Skin discomfort (0.8%)
Sunburn (1.6%)
Conjunctivitis (0.4%)
Sources:
https://www.fda.gov/media/71361/download
AEs

AEs

AESignificanceDosePopulation
Eczema 1.3%
3.7 g 1.3 times / day multiple, topical (median)
Recommended
Dose: 3.7 g, 1.3 times / day
Route: topical
Route: multiple
Dose: 3.7 g, 1.3 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 3.69 years (range: 0.64-48.15 years)
n = 79
Health Status: healthy
Age Group: 3.69 years (range: 0.64-48.15 years)
Sex: M+F
Population Size: 79
Sources:
https://www.fda.gov/media/71361/download
Dermatitis 2.5%
3.7 g 1.3 times / day multiple, topical (median)
Recommended
Dose: 3.7 g, 1.3 times / day
Route: topical
Route: multiple
Dose: 3.7 g, 1.3 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 3.69 years (range: 0.64-48.15 years)
n = 79
Health Status: healthy
Age Group: 3.69 years (range: 0.64-48.15 years)
Sex: M+F
Population Size: 79
Sources:
https://www.fda.gov/media/71361/download
Rosacea 0.4%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Taste perversion 0.4%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Conjunctivitis 0.8%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Seborrhea 0.8%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Sunburn 0.8%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Dry skin 1.2%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Eczema 1.2%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Erythema 1.2%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Skin discomfort 1.2%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Pruritus 2%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Dermatitis 2.8%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Acne 4.8%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
https://www.fda.gov/media/71361/download
Conjunctivitis 0.4%
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
https://www.fda.gov/media/71361/download
Eczema 0.4%
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
https://www.fda.gov/media/71361/download
Erythema 0.8%
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
https://www.fda.gov/media/71361/download
Skin discomfort 0.8%
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
https://www.fda.gov/media/71361/download
Sunburn 1.6%
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
https://www.fda.gov/media/71361/download
Dermatitis 2.8%
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
https://www.fda.gov/media/71361/download
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
inhibitor
1767
inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP3A4
1925
 no
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B5-01495
http://www.3bsc.com/index/pro_info.php?id=69114
AA Blocks
AA00342H
http://www.aablocks.com/goods/Goods/detail?id=AA00342H
AK Scientific, Inc. (AKSCI)
71158
http://www.aksci.com/item_detail.php?cat=71158
Aaron Chemicals
AR0034U9
http://www.aaronchem.com/70356-09-1
AbMole Bioscience
M5434
http://www.abmole.com/products/avobenzone.html
Acadechem
ACDS-036868
http://www.acadechemical.com/product/111567
Achemica
ACMC-209oe7
http://www.achemica.com/prodinfo/?id=130770
Achemtek
0104-012933
http://www.achemtek.com/70356-09-1
Acorn PharmaTech
ACN-S002307
http://www.acornpharmatech.com/
Angene
AGN-PC-0JKY2S
http://www.angenechemical.com/productshow/AGN-PC-0JKY2S.html
Anward
ANW-35885
http://www.anward.com/pro_result/1413
ApexBio Technology
B2079
http://www.apexbt.com/avobenzone.html
Ark Pharm
AK-48454
http://www.arkpharminc.com/products/70356-09-1.html
Aromsyn
AS04672
http://www.aromsyn.com/product/AS04672.html
Aurora Fine Chemicals LLC
A17.901.658
http://online.aurorafinechemicals.com/info?ID=A17.901.658
Avantor Inc
700004-106
https://us.vwr.com/store/product/21572552/1-4-tert-butylphenyl-3-4-methoxyphenyl-1-3-propanedione
Avantor Inc
700004-108
https://us.vwr.com/store/product/21572552/1-4-tert-butylphenyl-3-4-methoxyphenyl-1-3-propanedione
Avantor Inc
700004-110
https://us.vwr.com/store/product/21572552/1-4-tert-butylphenyl-3-4-methoxyphenyl-1-3-propanedione
BLD Pharm
BD51410
http://www.bldpharm.com/products/70356-09-1.html
BioCrick
BCC4891
http://www.biocrick.com/Avobenzone-BCC4891.html
BioSynth
Q-200661
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-200661.html
Boerchem
BC215936
http://www.boerchem.com/?product_36612.html
Chem Scene
CS-2356
http://www.chemscene.com/70356-09-1.html
ChemMol
30107627
http://www.chemmol.com/chemmol/30107627.html
ChemMol
44005429
http://www.chemmol.com/chemmol/44005429.html
ChemMol
49408542
http://www.chemmol.com/chemmol/49408542.html
ChemMol
99160632
http://www.chemmol.com/chemmol/99160632.html
Chemspace
CSSB00016988247
https://chem-space.com/CSSB00016988247
Clearsynth
CS-O-10849
https://www.clearsynth.com/en/CSO10849.html
DC Chemicals
DCAPI1313
http://www.dcchemicals.com//product_show-Avobenzone_Parsol_1789_.html
Finetech
FT-0623334
http://www.finetechnology-ind.com/prod/detail/pub/70356-09-1.html
Hairui
HR129959
http://www.hairuichem.com/en/product/70356-09-1.html
LGC Standards
DRE-C15894520
https://www.lgcstandards.com/US/en/p/DRE-C15894520
LGC Standards
LGCFOR0902.00
https://www.lgcstandards.com/US/en/p/LGCFOR0902.00
Lab Network
LN00193793
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00193793
MedChem Express
HY-B0316
https://www.medchemexpress.com/Avobenzone.html
MuseChem
A000883
https://www.musechem.com/product/A000883.html
Parchem
25912
http://www.parchem.com/chemical-supplier-distributor/Avobenzone-015912.aspx
Renno Tech
RL04694
http://www.rennotech.com/product_show.asp?id=4943
Sigma-Aldrich
16633_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/16633?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
PHR1073_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/phr1073?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
1045337_USP
https://www.sigmaaldrich.com/catalog/product/usp/1045337?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech
S021211
http://www.sinfoobiotech.com/product/1024609
Smolecule
S519867
http://www.smolecule.com/products/s519867
TCI (Tokyo Chemical Industry)
B3382
http://www.tcichemicals.com/eshop/en/us/commodity/B3382/index.html
THE BioTek
bt-261258
https://www.thebiotek.com/product/inhibitors/bt-261258
VladaChem
VL273859-100G
https://www.vladachem.com/product.php?products=70356-09-1
Yuhao Chemical
LT1520
http://www.chemyuhao.com/70356-09-1.html
abcr GmbH
AB261323
http://www.abcr.com/shop/en/AB261323
eNovation Chemicals
D669289
https://www.enovationchem.com/ProductDetails.asp?ProductID=D669289
iChemical
EBD34539
http://www.ichemical.com/products/70356-09-1.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
PubMed

PubMed

TitleDatePubMed
Multiple chemical sensitivities, including iatrogenic allergic contact dermatitis, in a patient with chronic actinic dermatitis: implications for management.
1996 Sep
Protection against UVB irradiation by natural filters extracted from lichens.
2002 Nov
Sunscreen penetration of human skin and related keratinocyte toxicity after topical application.
2005 Jul-Aug
A new long-chain UV absorber derived from 4-tert-butyl-4'-methoxydibenzoylmethane: absorbance stability under solar irradiation.
2005 Mar-Apr
Unexpected photolysis of the sunscreen octinoxate in the presence of the sunscreen avobenzone.
2005 Mar-Apr
Evaluation of the photostability of different UV filter combinations in a sunscreen.
2006 Jan 13
Changes in ultraviolet absorbance and hence in protective efficacy against lipid peroxidation of organic sunscreens after UVA irradiation.
2006 Mar 1
Design of a photostabilizer having built-in antioxidant functionality and its utility in obtaining broad-spectrum sunscreen formulations.
2006 May-Jun
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods.
2006 Nov
A new sunscreen agent.
2007 May 21
Photostability and efficacy studies of topical formulations containing UV-filters combination and vitamins A, C and E.
2007 Oct 1
In vitro assessments of UVA protection by popular sunscreens available in the United States.
2008 Dec
Assessing retinol stability in a hydroquinone 4%/retinol 0.3% cream in the presence of antioxidants and sunscreen under simulated-use conditions: a pilot study.
2008 Mar
Evaluation of spray congealing as technique for the preparation of highly loaded solid lipid microparticles containing the sunscreen agent, avobenzone.
2009 Aug
Optical and electron paramagnetic resonance studies of the excited states of 4-tert-butyl-4'-methoxydibenzoylmethane and 4-tert-butyl-4'-methoxydibenzoylpropane.
2009 Dec 3
Polymorphism and reversible mechanochromic luminescence for solid-state difluoroboron avobenzone.
2010 Feb 24
A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescription 0.02% tretinoin product regimen.
2010 Mar
Patents

Patents

JP2004099889A
1
JP2005239667A
3
JP2007182387A
1
JP2007182389A
1
JP2007261978A
2
JP2008162988A
1
JP2011506741A
5
JP4833491B2
3
JPH08217621A
2
JPH09227350A
1
JPS61215316A
1

Sample Use Guides

In Vivo Use Guide
apply liberally 15 min before sun exposure. reapply as needed or after towel drying, 40 min of swimming, or perspiring.
Route of Administration: Topical
In Vitro Use Guide
Sources: DOI: 10.7324/JAPS.2015.50611
Avobenzone 2% and ethyl ascorbic acid2% represented the best photostability with avobenzone concentrations decrease by 11,82% for 15 hour using UVA lamp irradiation 4,7 mW/cm2.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:23:18 GMT 2023
Edited
by admin
on Fri Dec 15 15:23:18 GMT 2023
Record UNII
G63QQF2NOX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AVOBENZONE
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
NEOHELIOPAN 357
Brand Name English
AVOBENZONE [USP-RS]
Common Name English
Avobenzone [WHO-DD]
Common Name English
NSC-758680
Code English
AVOBENZONE COMPONENT OF ANTHELIOS SX
Common Name English
AVOBENZONE COMPONENT OF SHADE UVAGUARD
Common Name English
1,3-PROPANEDIONE, 1-(4-(1,1-DIMETHYLETHYL)PHENYL)-3-(4-METHOXYPHENYL)-
Systematic Name English
ESCALOL 517
Brand Name English
4-METHOXY-4'-TERT-BUTYLDIBENZOYLMETHANE
Common Name English
BUTYL METHOXYDIBENZOYLMETHANE [INCI]
Common Name English
1-(4-TERT-BUTYLPHENYL)-3-(4-METHOXYPHENYL)PROPAN-1,3-DIONE
Systematic Name English
BUTYL METHOXYDIBENZOYLMETHANE
INCI  
INCI  
Official Name English
AVOBENZONE [MART.]
Common Name English
AVOBENZONE [USP IMPURITY]
Common Name English
AVOBENZONE [MI]
Common Name English
AVOBENZONE [HSDB]
Common Name English
CAPITAL SOLEIL COMPONENT AVOBENZONE
Common Name English
ANTHELIOS SX COMPONENT AVOBENZONE
Common Name English
avobenzone [INN]
Common Name English
EUSOLEX 9020
Brand Name English
AVOBENZONE [ORANGE BOOK]
Common Name English
AVOBENZONE [USP MONOGRAPH]
Common Name English
AVOBENZONE COMPONENT OF CAPITAL SOLEIL
Common Name English
AVOBENZONE [USAN]
Common Name English
PARSOL 1789
Brand Name English
SHADE UVAGUARD COMPONENT AVOBENZONE
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 142401
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
NCI_THESAURUS C851
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
CFR 21 CFR 352.10
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
Code System Code Type Description
EVMPD
SUB05617MIG
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
RXCUI
45045
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY RxNorm
USAN
AA-89
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
WIKIPEDIA
AVOBENZONE
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
INN
6480
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
FDA UNII
G63QQF2NOX
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
PUBCHEM
51040
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
ChEMBL
CHEMBL1200522
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
EPA CompTox
DTXSID9044829
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
HSDB
7423
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
DAILYMED
G63QQF2NOX
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
ECHA (EC/EINECS)
274-581-6
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
MERCK INDEX
m2151
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY Merck Index
RS_ITEM_NUM
1045337
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
NCI_THESAURUS
C47406
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
NSC
758680
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
DRUG CENTRAL
4242
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
CAS
70356-09-1
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
DRUG BANK
DB09495
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
SMS_ID
100000086882
Created by admin on Fri Dec 15 15:23:18 GMT 2023 , Edited by admin on Fri Dec 15 15:23:18 GMT 2023
PRIMARY
Related Record Type Details
Structure of AVOBENZONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966